Aurinia Pharmaceuticals 2017 Corporate Presentation Voclosporin

Aurinia Pharmaceuticals clinical-stage biopharmaceutical company overview presenting lead program voclosporin, a Phase III calcineurin-inhibitor candidate for lupus nephritis treatment. Deck outlines company positioning, market opportunity in the multi-billion dollar nephrology space, intellectual property protection through 2027, and seasoned management team focused on addressing high unmet medical need in autoimmunity.